Compare Adaptive Biotechnologies Corp (ADPT) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Best Buy Co Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Best Buy Co Inc trades at $77.65 (market cap $16.59B). The key difference: Best Buy Co Inc is far larger — about 5× Adaptive Biotechnologies Corp's market cap, and Best Buy Co Inc pays a 4.88% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BBY | |
|---|---|---|
Market Cap | $3.33B | $16.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $84.00 |
52-Week Low | $10.24 | $55.52 |
Enterprise Value | $3.19B | $18.97B |
Dividend Yield | — | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Best Buy (BBY) trades at $78.72, up 0.94% with a bullish technical outlook and positive earnings momentum after beating estimates for three consecutive quarters. The company shows strong profitability with 39.1% ROE and attractive valuation metrics including a 14.44 P/E ratio. Recent leadership transition and strategic focus on higher-margin businesses like marketplace expansion and retail media provide growth catalysts.
The stock offers value with a 5.11% dividend yield and 5% upside to consensus price target of $82.18, though revenue declines and competitive pressures in consumer electronics remain key risks. Analyst sentiment is mixed with 34% buy ratings versus 53% hold, reflecting cautious optimism about the turnaround strategy under new CEO Jason Bonfig.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
